President Donald Trump’s administration is preparing a new probe into U.S. trading partners over drug pricing, Aime Williams and George Parker of The Financial Times reports. The investigations will consider if any U.S. trading partners are underpaying for drugs, three people familiar with the matter told the Times. Trump has repeatedly commented that other countries pay less than the U.S. for the same medicines and plans to take action against nations that refuse to “equalize” prices. Publicly traded drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), Novo Nordisk (NVO), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Companies involved the sale of pharmaceuticals include CVS Health (CVS), Cigna (CI), UnitedHealth (UNH), Cardinal Health (CAH), McKesson (MCK) and Cencora (COR).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Bicara sinks after J&J reports head and neck cancer data
- Activist Jana Partners Takes Stake in Cooper Companies, Presses for Strategic Review
- Johnson & Johnson announces new results from Phase 1b/2 OrigAMI-4 study
- Kenvue Stock (KVUE) Plunges on Legal Woes Related to Talc Products
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!